IP Library Granted Patent US 9,181,254
Granted Patent B2
US 9,181,254 · App. 14/398,884 · Granted Nov 10, 2015

Method for producing sepiapterin and tetrahydrolactoylpterin

Inventors: Hiroshi Yoshino (Narashino, JP); Taichi Komoda (Narashino, JP); Yuichi Shiro (Chiba, JP); Shunichi Murata (Narashino, JP); Shizuaki Murata (Mie-gun, JP); Yasuhiro Kuroda (Yokkaichi, JP)
Assignee: SHIRATORI PHARMACEUTICAL CO., LTD.
C07D475/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,181,254
App. No.
14/398,884
Granted
Nov 10, 2015
Kind
B2
Abstract

To provide a method for producing sepiapterin, lactoylpterin or tetrahydrolactoylpterin. Sepiapterin, lactoylpterin and tetrahydrolactoylpterin are produced at high yield through the following reaction scheme.

Claims (20)

1. A method for producing sepiapterin represented by formula (3):

or a salt thereof, the method comprising:

subjecting lactoylpterin represented by formula (2):

or a salt thereof to reduction by use of a sulfite, a hyposulfite or a thiosulfate, or catalytic reduction under basic conditions.

2. A method for producing sepiapterin represented by formula (3):

or a salt thereof, the method comprising:

subjecting tetrahydrolactoylpterin represented by formula (4):

or a salt thereof to oxidation by use of a peracid, or air oxidation under neutral or basic conditions.

3. A method for producing tetrahydrolactoylpterin represented by formula (4):

or a salt thereof, the method comprising:

subjecting lactoylpterin represented by formula (2):

or a salt thereof to reduction by use of a BH 3 -based reducing agent, or catalytic reduction under basic conditions.

4. The method according to claim 3 , wherein the reduction reaction is reduction by use of a BH 3 -based reducing agent under acidic conditions, or catalytic reduction under basic conditions.

5. A method for producing sepiapterin represented by formula (3):

or a salt thereof, the method comprising:

subjecting lactoylpterin represented by formula (2):

or a salt thereof to reduction by use of a BH 3 -based reducing agent, or catalytic reduction under basic conditions, to thereby form tetrahydrolactoylpterin represented by formula (4):

or a salt thereof, and

subsequently subjecting the compound (4) to oxidation by use of a peracid, or air oxidation under neutral or basic conditions.

6. The method according to claim 5 , wherein the reduction reaction is reduction by use of a BH 3 -based reducing agent under acidic conditions, or catalytic reduction under basic conditions.

Assignments (3)
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT @ REEL 061584 AND FRAME 0377 Recorded Oct 23, 2023
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: PTC THERAPEUTICS MP, INC.
Reel/Frame 065321/0025 →
SECURITY INTEREST Recorded Oct 28, 2022
From: PTC THERAPEUTICS MP, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 061584/0377 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 4, 2014
From: YOSHINO, HIROSHI; KOMODA, TAICHI; SHIRO, YUICHI; MURATA, SHUNICHI; MURATA, SHIZUAKI; KURODA, YASUHIRO
To: SHIRATORI PHARMACEUTICAL CO., LTD.
Reel/Frame 034101/0116 →
Priority Claims (2)
JP 2012-105758 · May 7, 2012 · national
JP 2012-247255 · Nov 9, 2012 · national
Continuity (1)
Related Publication 20150119574A1 · Apr 30, 2015